Wellspect HealthCare Establishes Strategic Advisory Board and Appoints Paul Moraviec and Michael Frazzette

New Strategic Advisory Board supports Wellspect HealthCare’s next phase of growth, with external advisors bringing extensive experience in global MedTech, urology, commercial growth and healthcare leadership.

Mölndal, Sweden – August 07, 2026 – Wellspect HealthCare, a subsidiary of Dentsply Sirona and a rapidly expanding global provider of innovative medical devices dedicated to improving the quality of life for individuals with bladder and bowel dysfunction, today announced the appointment of Paul Moraviec and Michael (Mike) Frazzette as external advisors to its Strategic Advisory Board.

The Strategic Advisory Board will provide strategic guidance on Wellspect’s long-term priorities, including market expansion, innovation and growth opportunities in adjacent sectors. While the Advisory Board is comprised of a mix of internal executives and external experts, it is intended to operate as a focused strategic forum that brings together diverse functional expertise and enterprise-wide perspectives to support Wellspect’s continued growth and success. The Board’s creation follows Dentsply Sirona’s previously announced decision to retain Wellspect HealthCare as a portfolio business. It is part of a governance approach designed to support Wellspect with greater focus, accountability, and strategic alignment while enabling Wellspect to operate with the autonomy needed to execute its growth strategy.

Adding external expertise to support Wellspect’s growth priorities

Paul Moraviec, former Chief Executive Officer of ConvaTec Group Plc, brings more than three decades of international healthcare and MedTech leadership experience. Mike Frazzette, former President and Chief Executive Officer of Laborie Medical Technologies, joins with more than 30 years of global healthcare, medical device and diagnostics leadership experience.

“Wellspect has a clear ambition to double the number of patients we serve by 2030,” says Chris Schlenk, Group Vice President at Wellspect HealthCare. “Paul and Mike bring deep MedTech leadership experience and a strong understanding of how to scale healthcare companies. Their perspectives will be valuable as we continue to focus on growth, innovation and improving outcomes for the people who rely on our solutions.”

“The Strategic Advisory Board is one part of our plan supporting Wellspect’s next phase of growth within Dentsply Sirona,” says Dan Scavilla, President and Chief Executive Officer at Dentsply Sirona. “It reflects our confidence in the long-term growth potential of the business and its leadership position in continence care.”

About Paul Moraviec

As Chief Executive Officer of ConvaTec Group Plc, Paul successfully led the global MedTech company through a major business transformation and its 2016 initial public offering on the London Stock Exchange. His experience spans global commercial operations, continence care, diabetes care, neurosurgery and medical technology, with prior leadership roles at Abbott, Johnson & Johnson, Bausch & Lomb and other healthcare companies. He has also served in advisory and board roles across the global MedTech sector.

About Mike Frazzette

Mike Frazzette brings more than 30 years of healthcare, medical device and diagnostics leadership experience. He most recently served as President and Chief Executive Officer of Laborie Medical Technologies, a global MedTech company focused on urology, gastroenterology and OB/GYN diagnostics and therapies. During his tenure, Laborie expanded significantly through organic growth, global expansion and strategic acquisitions. Frazzette previously held senior executive roles at Smith & Nephew and Tyco Healthcare and currently serves on private healthcare company boards.
A focused structure to support growth and innovation

The full Strategic Advisory Board will include Moraviec and Frazzette alongside Wellspect and Dentsply Sirona leadership: Dan Scavilla, President and Chief Executive Officer, Dentsply Sirona; Chris Schlenk, Group Vice President, Wellspect HealthCare; and Lindi Barton-Brobst, SVP, General Counsel, Dentsply Sirona.

Wellspect’s growth strategy is supported by continued investment in innovation, including its product pipeline and upcoming launches intended to address evolving needs in continence care and adjacent categories. The company’s portfolio includes trusted brands such as LoFric®, Navina™ and Surity™, and Wellspect continues to work closely with healthcare professionals and users to improve clinical outcomes and quality of life.

Wellspect has been a trusted leader in healthcare for more than 40 years.

For more details, please contact:

Marion Par-Weixlberger | Vice President Public Relations, Corporate Communications & Brand
Sirona Straße 1 | 5071 Wals bei Salzburg | Austria 

T +43 (0) 662 2450-588 | F +43 (0) 662 2450-540 

publicrelations@dentsplysirona.com

About Wellspect HealthCare

Wellspect HealthCare, a subsidiary of Dentsply Sirona, is a leading global provider of innovative medical devices dedicated to improving the quality of life for individuals with bladder and bowel dysfunction.

With approximately 1,200 employees worldwide, Wellspect is committed to making a real difference for people managing continence care needs, empowering them to live each day to the fullest.

Wellspect delivers solutions that support safe bladder and bowel management, while continuously enhancing the experience, clinical performance, and service quality for both healthcare professionals and the people in their care.

As one of the world’s leading manufacturers of intermittent urinary catheters, Wellspect has been at the forefront of innovation since 1983 with its LoFric® brand, which introduced the first hydrophilic-coated catheter.

Wellspect has also pioneered the development of Navina™, an innovative transanal irrigation system designed to support individuals living with chronic bowel disorders.

With advanced Surity™, Wellspect provides reliable urinary incontinence care designed to restore comfort, rest, and confidence for people living with severe urinary incontinence and for their caregivers.

Every day, Wellspect strives to maintain the highest quality standards while minimizing the environmental impact of its products.

Headquartered in Mölndal, Sweden, Wellspect operates in more than 40 countries, offering life-enhancing solutions to people around the world. Dentsply Sirona, the world’s largest diversified manufacturer of professional dental products and technologies, is listed on Nasdaq under the symbol XRAY.